Collaboration With Torrey Pines Adds To BioMotiv’s Early Momentum
This article was originally published in The Pink Sheet Daily
Executive Summary
The Cleveland-based biopharma accelerator company signs a $40 million agreement with Torrey Pines Investment to provide early-stage funding and development for innovations emerging from academic research. Previously, BioMotiv raised $46 million from investors to fund its model of accelerating breakthrough discoveries into mid-stage development.